136 related articles for article (PubMed ID: 8305539)
1. In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy.
Schwartzentruber DJ
Curr Opin Oncol; 1993 Nov; 5(6):1055-8. PubMed ID: 8305539
[TBL] [Abstract][Full Text] [Related]
2. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
3. Relapse after successful treatment with immunotherapy: lessons for the future.
Fisher RI
Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407
[No Abstract] [Full Text] [Related]
4. Treatment of metastatic melanoma and renal cell carcinoma with interleukin-2.
Manson LA
JAMA; 1994 Nov; 272(17):1327. PubMed ID: 7933390
[No Abstract] [Full Text] [Related]
5. Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S2-6. PubMed ID: 9457385
[No Abstract] [Full Text] [Related]
6. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
Kradin RL; Kurnick JT; Lazarus DS; Preffer FI; Dubinett SM; Pinto CE; Gifford J; Davidson E; Grove B; Callahan RJ
Lancet; 1989 Mar; 1(8638):577-80. PubMed ID: 2564111
[TBL] [Abstract][Full Text] [Related]
8. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
9. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Sherry RM; Pass HI; Rosenberg SA; Yang JC
Cancer; 1992 Apr; 69(7):1850-5. PubMed ID: 1551067
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2: sunrise for immunotherapy?
Lancet; 1989 Feb; 1(8633):308. PubMed ID: 2563463
[No Abstract] [Full Text] [Related]
11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy comes of age.
Rosenberg SA
Nat Clin Pract Oncol; 2005 Mar; 2(3):115. PubMed ID: 16264884
[No Abstract] [Full Text] [Related]
13. Interleukin-2.
Med Lett Drugs Ther; 1987 Sep; 29(749):88-9. PubMed ID: 3306301
[No Abstract] [Full Text] [Related]
14. The role of adoptive immunotherapy in solid cancers.
Kruit WH; Stoter G
Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332
[No Abstract] [Full Text] [Related]
15. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations.
Whiteside TL
In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for metastatic cancer. Establishing a 'proof of principle'.
Hellman S
JAMA; 1994 Mar 23-30; 271(12):945-6. PubMed ID: 8120965
[No Abstract] [Full Text] [Related]
17. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
18. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
19. Immunotherapy of renal cell carcinoma.
Haas GP; Hillman GG; Redman BG; Pontes JE
CA Cancer J Clin; 1993; 43(3):177-87. PubMed ID: 8490757
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
